The results indicate a possibility of the use of IL-33 as a biomarker for liver fibrosis progress in patients suffering from CHC, whereas IL-17 and IL-25 could be used as biomarkers for the development of hepatocellular carcinoma. The gene discussed is IL25; the disease is Hepatic fibrosis.